Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: A novel polymer-conjugation technique with a reversible amino- protective reagent

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 1, 1999, Pages 368-372

  Tsunoda, Shinichi ^a   Ishikawa, Tomoyoshi ^a   Yamamoto, Yoko ^a   Kamada, Haruhiko ^a   Koizumi, Keiichi ^a   Matsui, Junji ^a   Tsutsumi, Yasuo ^a   Hirano, Takashi ^b   Mayumi, Tadanori ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATL INST BIOSCI HUM TECHNOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENDOPEPTIDASES; FEMALE; FIBROSARCOMA; HYDROLYSIS; INDICATORS AND REAGENTS; MALEIC ANHYDRIDES; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; POLYETHYLENE GLYCOLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032967784     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bollon AP, Berent SL, Torczynski RM, Hill NO, Lemeshev Y, Hill JM, Jia FL, Joher A, Pichyangkul S and Khan A (1988) Human cytokines, tumor necrosis factor, and interferons: Gene cloning, animal studies, and clinical trials. J Cell Biochem 36:353-367.
2. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N and Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3670.
3. Delgado C, Francis GE and Fisher D (1992) The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9:249-304.
4. Donohue JH and Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203-2208.
5. Gaskill HV 3d (1988) Continuous infusion of tumor necrosis factor: Mechanisms of toxicity in the rat. J Surg Res 44:664-671.
6. Helson L, Green S, Carswell E and Old LJ (1975) Effect of tumour necrosis factor on cultured human melanoma cells. Nature (London) 258:731-732.
7. Kaneda Y, Yamamoto Y, Kamada H, Tsunoda S, Tsutsumi Y, Hirano T and Mayumi T (1998) Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice. Cancer Res 58: 290-295.
8. Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Furue H, Hattori T, Ichihashi H, Inoguchi K, Majima H, Niitani H, Ota K, Saito T, Suga S, Suzuoki Y, Wakui A, Yamada K and the α-TNF Cooperative Study Group (1987) Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20:223-229.
9. Maeda M, Kawasaki K, Mu Y, Kamada H, Tsutsumi Y, Smith TJ and Mayumi T (1998) Amino acids and peptides. XXXIII. A bifunctional polylethylene glycol) hybrid of laminin-related peptides. Biochem Biophys Res Commun 248:485-489.
10. Ostensen ME, Thiele DL and Lipsky PE (1987) Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol 138:4185-4191.
11. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 alone. N Engl J Med 316:889-897.
12. Starnes HF Jr, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W, Oettgen HF and Brennan MF (1988) Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest 82:1321-1325.
13. Stocks SJ, Jones AJ, Ramey CW and Brooks DE (1986) A fluorometric assay of the degree of modification of protein primary amines with polyethylene glycol. Anal Biochem 154:232-234.
14. Swerlick RA, Lee KH, Li LJ, Sepp NT, Caughman SW and Lawley TJ (1992) Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol 149:698-705.
15. Tanaka H and Tokiwa T (1990) Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res 50:6615-6619.
16. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ 3d, Zentella A, Albert JD and Shires GT (1986) Shock and tissue injury induced by recombinant human cachectin. Science (Wash DC) 234:470-074.
17. Tracey KJ (1992) TNF and other cytokines in the metabolism of septic shock and cachexia. Clin Nutr 11:1-11.
18. Tsutsumi Y, Kihira T, Tsunoda S, Kamada H, Nakagawa S, Kaneda Y, Kanamori T and Mayumi T (1996a) Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. J Pharmacol Exp Ther 278:1006-1011.
19. Tsutsumi Y, Kihira T, Tsunoda S, Kanamori T, Nakagawa S and Mayumi T (1995) Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br J Cancer 71:963-968.
20. Tsutsumi Y, Tsunoda S, Kamada H, Kihira T, Kaneda Y, Ohsugi Y and Mayumi T (1996b) PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb Haemost 77:168-173.
21. Van Ostade X, Tavernier J, Prange T and Fiers W (1991) Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. EMBO J 10:827-836.
22. Yamazaki S, Onishi E, Enami K, Natori K, Kohase M, Sakamoto H, Tanouchi M and Hayashi H (1986) Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn J Med Sci Biol 39:105-118.